Mesial temporal lobe epilepsy with hippocampal sclerosis
MONDO:0020476Mesial temporal lobe epilepsy with hippocampal sclerosis is a rare epilepsy syndrome defined by seizures originating in limbic areas of the mesial temporal lobe, particularly in the hippocampus, amygdala, and in the parahippocampal gyrus and its connections, and hippocampal sclerosis, usually unilateral or asymmetric. It is frequently associated with an initial precipitating event, such as febrile seizures, hypoxia, intracranial infection or head trauma, most often occurring in the first five years of life, followed by a latent period without seizures. Typical seizures consist of a characteristic aura that is frequently a rising epigastric sensation associated with emotional disturbances, illusions, and autonomic symptoms (widened pupils, palpitations), progressive impairment of consciousness, oro-alimentary automatisms (lip smacking, chewing, licking, tooth grinding), behavioral arrest, head deviation, dystonic postures, hand and verbal automatisms. Seizures are followed by postictal dysfunction. Initially, seizures are easily controlled with antiepileptic drugs, later they frequently become refractory and associated with progressive behavioral changes and memory deficits.
Also known as: MTLE-HS
19 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis study follows 158 people in France who are prescribed Epidyolex (a cannabidiol-based medicine) for seizures as part of their normal care. Researchers will track how long people stay on the treatment, side effects, seizure frequency, and changes in daily functioning and quali…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Brain zaps for seizures: tiny trial tests new target
Disease control OngoingThis pilot study tests whether deep brain stimulation (DBS) of a brain region called the subiculum can safely reduce seizures in 6 people with drug-resistant temporal lobe epilepsy and bilateral hippocampal sclerosis. Participants receive a DBS device, and researchers track seizu…
Phase: NA • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
AI boosts brain scan accuracy in massive new trial
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether an AI tool can help radiologists read brain CT and MRI scans more accurately and quickly. Researchers will compare how well doctors, AI alone, and doctors using AI together can spot abnormalities, urgent findings, and classify diseases. The goal is to red…
Sponsor: Yaou Liu • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Sound waves aimed at the brain could ease seizures
Symptom relief ENROLLING_BY_INVITATIONThis small study tests whether low-intensity focused ultrasound (LIFU) can safely reduce seizures in people with temporal lobe epilepsy that doesn't improve with medication. Six participants with implanted brain electrodes will receive both real and sham ultrasound sessions. The …
Phase: NA • Sponsor: Carilion Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Zapping the Brain's memory network: a new hope for epilepsy?
Knowledge-focused ENROLLING_BY_INVITATIONThis pilot study at the University of Chicago is testing whether a non-invasive brain stimulation technique called TMS can improve memory and reduce seizure-related brain activity in people with mesial temporal lobe epilepsy (MTLE). Thirty-four adults with drug-resistant MTLE wil…
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:21 UTC
-
300 volunteers help create medical image bank for science
Knowledge-focused OngoingThis study gathers MRI, CT, and ultrasound images from 300 adults—some healthy, some with kidney or brain disease—to build a collection for future not-for-profit research. No new treatments are being tested; the goal is to make medical images available to scientists for advancing…
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:28 UTC